article thumbnail

Controlling lipid levels with fewer side effects possible with new drug

Science Daily - Heart Disease

Mice administered the drug showed decreased lipid levels in the liver and blood, with fewer side effects in the liver, heart, and bones compared to existing compounds. The findings suggest an effective treatment for lipid disorders such as dyslipidemia.

article thumbnail

Creative Alliances in Cardiorenal Metabolic Management: A Game Changer (Part 1) 

Cardiometabolic Health Congress

Key contributions: Advanced cardiac imaging (e.g., high-sensitivity troponin, NT-proBNP) in risk stratification Utilization of advanced echocardiographic techniques (e.g.,

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

Food and Drug Administration ( FDA ) has approved an additional indication for Wegovy ( semaglutide ) to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along with a reduced calorie diet and increased physical activity.

Obesity 111